Network Analysis of Adult MDD and ADHD

Network Analysis of Co-morbid Symptoms of Adult Major Depressive Disorder and Attention-deficit Hyperactivity Disorder in an Outpatient Population

The study is an investigation to determine co-morbid symptoms between adult major depressive disorder (MDD) and adult attention-deficit hyperactivity disorder (ADHD) using a novel statistical technique called network analysis.

Study Overview

• Status: Unknown
• Conditions: ADHD

• Study Type: Observational
• Enrollment (Anticipated): 500

Contacts and Locations

• Study Contact: Name: Kuppuswami Shivakumar, M.D.; Phone Number: 8234 705-523-7100; Email: kshivakumar@hsnsudbury.ca

Study Locations

• Canada
  • Ontario
    • Sudbury, Ontario, Canada, P3E 1X3
      • Recruiting
      • Kirkwood Site - Health Sciences North
      • Contact: Kevin Saroka, Ph.D.; Phone Number: 8260 705-523-7100; Email: ksaroka@hsnsudbury.ca

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 60 years (ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

We will gather a recruitment of 500 male and female outpatients from the Psychiatric Outpatient Clinic at Kirkwood Site attached to Health Sciences North.

Description

Inclusion Criteria:

• participants have a diagnosis of MDD or ADHD or both
• participants are competent to consent to the study

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Co-morbidity	Characterize the ADHD/MDD symptom network in a psychiatric outpatient setting comprised of adults	September 8, 2021
Network reliability	Determine the stability and reliability of this network	September 8, 2021
Central symptoms	Determine the central symptoms that lead to co-activation of ADHD/MDD clusters	September 8, 2021

Collaborators and Investigators

• Sponsor: Health Sciences North Research Institute

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 21, 2018
• Primary Completion (ANTICIPATED): August 8, 2021
• Study Completion (ANTICIPATED): September 8, 2021

Study Registration Dates

• First Submitted: August 5, 2020
• First Submitted That Met QC Criteria: August 5, 2020
• First Posted (ACTUAL): August 7, 2020

Study Record Updates

• Last Update Posted (ACTUAL): August 7, 2020
• Last Update Submitted That Met QC Criteria: August 5, 2020
• Last Verified: August 1, 2020

More Information

Terms related to this study

• Other Study ID Numbers: 18-056

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: None of the IPD will be shared with other researchers

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No